CSIMarket Company Name, Ticker, Suppliers, else..
 
Abvc Biopharma Inc  (NASDAQ: ABVC)
 
Price: $2.2300 $0.00 0.000%
Day's High: $2.28 Week Perf: -11.86 %
Day's Low: $ 2.19 30 Day Perf: -21.75 %
Volume (M): 81 52 Wk High: $ 5.48
Volume (M$): $ 180 52 Wk Avg: $1.87
Open: $2.20 52 Wk Low: $0.40



 Market Capitalization (Millions $) 52
 Shares Outstanding (Millions) 23
 Employees 29
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Abvc Biopharma Inc
Abvc Biopharma Inc is a pharmaceutical company that specializes in the research, development, and commercialization of innovative therapies for various diseases and medical conditions. They focus on biologics, which are medications created from living organisms or contain components of living organisms. Their team of scientists and researchers work diligently to discover and develop novel treatments that can improve the lives of patients worldwide. Abvc Biopharma Inc is dedicated to providing safe and effective solutions to address unmet medical needs and make a positive impact on global healthcare.


   Company Address: 44370 Old Warm Springs Blvd. Fremont 94538
   Company Phone Number: 668-0881   Stock Exchange / Ticker: NASDAQ ABVC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.01%    
LLY        0.82% 
MGNX        1.45% 
PFE   -1.33%    
REGN        0.47% 
VRTX   -2.78%    
• View Complete Report
   



Product Service News

ABVC BioPharma Pioneering a New Era in Mental Health with Promising Alternative to Prozac

Published Thu, Dec 19 2024 1:31 PM UTC

In a remarkable turn of events for mental health treatment, ABVC BioPharma, Inc. (NASDAQ: ABVC), headquartered in Fremont, California, has made significant strides toward revolutionizing therapeutic modalities for mental health disorders. With the recent discontinuation of Prozac long a staple antidepressant amid escalating concerns over its side effects the company aims to ...
Announcement

ABVC BioPharma Pivots Forward Despite Revenue Decline via Global Licensing Deal in NSCLC Treatment

Published Wed, Apr 17 2024 1:01 PM UTC

The clinical-stage biopharmaceutical company, ABVC BioPharma Inc. (NASDAQ: ABVC), publicized a new global definitive licensing deal with OncoX, a dietary supplements specialist in oncology. The deal focuses on propelling treatment options for Non-Small Cell Lung Cancer (NSCLC). ABVC and its associate, Rgene Corporation, will tackle clinical testing, registration, manufacturi...
Licensing Agreement

ABVC BioPharma Forms Global Licensing Agreement for Oncology/Hematology Product Line, Securing Lucrative Revenue Opportunities

Published Wed, Apr 10 2024 12:30 PM UTC

In a significant development, ABVC BioPharma, a renowned clinical-stage biopharmaceutical company, has successfully executed a global licensing term sheet with OncoX BioPharma. This collaboration aims to encompass ABVC s promising pipeline of Oncology/Hematology products, with the potential to generate substantial licensing income and royalties. This groundbreaking agreement...
Licensing Agreement

ABVC BioPharma Secures Global Licensing Deal for Vitargus Device Valued at $187M, Ensuring Potential Income of $33.5M and Royalties of $60M

Published Tue, Mar 26 2024 12:30 PM UTC

ABVC BioPharma, a clinical-stage biopharmaceutical company specializing in ophthalmology, CNS, and oncology/hematology, has announced a significant global licensing deal for its medical device, Vitargus. The company, along with its subsidiary BioFirst Corporation, entered into an agreement with ForSeeCon Eye Corporation (FEYE) to license the Ophthalmology pipeline, including...
Product Service News

ABVC BioPharma Expands into Lucrative Cancer Market with Innovative Combination Therapy and Dietary Supplements Derived from Maitake Mushroom

Published Tue, Feb 27 2024 1:31 PM UTC

In a recent update, ABVC BioPharma, Inc. has announced its new direction in the fields of oncology and hematology, aiming to tap into the lucrative cancer market. The company, known for its development of therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, revealed its plans for combination therapy for cancer treatment and immunity...






Abvc Biopharma Inc's Segments





Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.